Edgewise Therapeutics Inc
$ 32.17
-0.86%
22 Apr - close price
- Market Cap 3,480,929,000 USD
- Current Price $ 32.17
- High / Low $ 32.93 / 31.87
- Stock P/E N/A
- Book Value 4.92
- EPS -1.63
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -0.34 %
- 52 Week High 35.00
- 52 Week Low 12.15
About
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The company is headquartered in Boulder, Colorado.
Analyst Target Price
$41.08
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-20 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-22 | 2023-11-09 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.47 | -0.39 | -0.34 | -0.43 | -0.42 | -0.36 | -0.34 | -0.33 | -0.47 | -0.41 | -0.34 | -0.36 |
| Estimated EPS | -0.4359 | -0.4 | -0.42 | -0.4211 | -0.4222 | -0.37 | -0.34 | -0.39 | -0.43 | -0.4 | -0.4 | -0.36 |
| Surprise | -0.0341 | 0.01 | 0.08 | -0.0089 | 0.0022 | 0.01 | 0 | 0.06 | -0.04 | -0.01 | 0.06 | 0 |
| Surprise Percentage | -7.8229% | 2.5% | 19.0476% | -2.1135% | 0.5211% | 2.7027% | 0% | 15.3846% | -9.3023% | -2.5% | 15% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.5 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EWTX
2026-04-20 21:46:00
This article provides an analysis of Edgewise Therapeutics Inc. (NASDAQ: EWTX), highlighting strong sentiment across all horizons and an exceptional 44.6:1 risk-reward short setup. It details AI-generated trading strategies for different risk profiles, including long, breakout, and risk hedging strategies, along with multi-timeframe signal analysis. The report also notes key support and resistance levels for near-term, mid-term, and long-term horizons, based on quantitative research.
2026-04-14 03:09:32
Edgewise Therapeutics (EWTX) stock reached a new 52-week high of $34.06, marking a 187% increase over the past year. The biotech firm, specializing in treatments for rare muscle disorders, has seen its market capitalization rise to $3.63 billion, driven by positive market sentiment and advancements in its product pipeline. Despite its current unprofitability, analysts maintain positive ratings and price targets, anticipating future catalysts.
2026-04-13 19:39:34
Edgewise Therapeutics Inc. (EWTX) stock reached a new 52-week high of $34.06, reflecting a 187% increase over the past year and a 123% return in the last six months. Despite its strong market performance, the company remains unprofitable with an EPS of -1.63 USD, and analysis suggests the stock may be overvalued. Analysts from Raymond James, Truist Securities, Evercore ISI, and JPMorgan have reiterated "Buy" or "Outperform" ratings with price targets up to $46, following positive data from the MESA study for its Becker muscular dystrophy treatment, sevasemten, and anticipation of upcoming EDG-7500 data in 2026.
2026-04-13 10:39:00
Analysts are optimistic about Edgewise Therapeutics (NASDAQ:EWTX) due to its innovative drug candidate, EWTX-101, which targets rare kidney and neuromuscular diseases. A consensus price target of $38.44 has been set, with most analysts issuing 'Buy' or 'Strong Buy' ratings. The company's stock has risen over 30% year-to-date, showing strong commercial potential for its pipeline focused on unmet medical needs.
2026-04-09 20:09:03
This article analyzes the behavioral patterns and institutional flows of Edgewise Therapeutics Inc. (NASDAQ: EWTX), indicating a near-term neutral sentiment amidst mid and long-term strength. It highlights an exceptional risk-reward short setup and provides three distinct AI-generated trading strategies with specific entry, target, and stop-loss zones for different risk profiles. The analysis includes multi-timeframe signal analysis with support and resistance levels.
2026-04-07 07:09:25
Aberdeen Group plc significantly increased its stake in Edgewise Therapeutics (NASDAQ:EWTX) by 32.6% in Q4, acquiring over 200,000 additional shares. This move brings their total holdings to 821,940 shares, representing approximately 0.78% of the company. Despite some insider selling from a director and CMO, Edgewise Therapeutics maintains a "Moderate Buy" consensus rating from analysts, with an average price target of $38.44.
